McLearn Healthcare sele

McLearn Healthcare sele

Shares of HCL Technologies (HCL) rallied 0.85% to Rs 940.50 apiece after it has been selected by McLaren Health Care, a fully integrated health network committed to quality, evidence-based patient care and cost efficiency, to provide digital transformation, standup a global EMR (Electronic Medical Record) Center of Excellence, and enable higher standards of service to members, providers, and employees.
The partnership will have HCL deliver IT services for all 15 McLaren system hospitals located in Michigan and Ohio. HCL services would include managing and transforming the digital infrastructure foundation and the core clinical and non-clinical applications utilizing HCL’s DRYICE automation framework.
This news follows CLSA’s decision to remove HCL Tech from its focus portfolio as the global brokerage is bullish on financials due to recent underperformance.
CLSA has added Axis Bank to its India portfolio, replacing HCL Tech, as CLSA reduces weight in defensives after their strong outperformance in the last two months.
CLSA’s defensive index has outperformed the Nifty by 3 percentage points in the last two months helped by a strong performance of pharma and the power sector. After this, relative valuations of defensives are no longer as attractive.
HCL Technologies is a leading global IT services company that helps global enterprises reimagine and transform their businesses through digital technology transformation.

Disclaimer –
This document is meant for the recipient only for use as intended and not for circulation. This document should not be reproduced or copied or made available to others. The information contained herein is from the public domain or sources believed to be reliable. While reasonable care has been taken to ensure that information given is at the time believed to be fair and correct and opinions based thereupon are reasonable, due to the very nature of research it cannot be warranted or represented that it is accurate or complete and it should not be relied upon as such. Also above note is not a recommendation to Buy or SELL and is only a view based on facts and figures and we will be in no way responsible for any losses incurred by anyone who uses this information to either trade or invests securities mentioned herein.